S*BIO takes $26M for cancer therapeutics
Pharmaceutical company S*BIO announced today that it raised $26 million in second-round funding to help push two new cancer treatment candidates through a second phase of clinical trials. Aravis Venture Associates and Bio*One Capital led the round, which also included Lacuna Apo BioTech and Zurcher Kantonalbank.
The Singapore-based company, which also has offices in Redwood City, Calif., has raised a total of $100 million since its inception in 2000. It received seed funding from Singapore Economic Development Board Investments and Chiron, reports VentureWire.
It will use its new funds to move its lead drugs from first to second-phase clinical trials. Both are cancer fighting compounds capable of targeting very specific disease-causing agents.
Next Story: Roundup: Web data offers election insight, banks gets big bonuses and more
Previous Story: Economic indicators jump — but start-up headache still setting in
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.